Ironwood Pharmaceuticals (IRWD) risk factors, FY2025 10-K

Ironwood Pharmaceuticals's FY2025 10-K, filed Feb 26, 2026, lists 46 risk factors in 6 groups. Against the prior year's 43: 12 new, 9 dropped, 14 substantially reworded.

Open IRWD in Gloom →
Ironwood Pharmaceuticals' chart, financials and news, free in your browser.Open IRWD in Gloom →
Risk factors listed
466 groups
New this year
12vs 43 last year
Dropped
9since the prior 10-K
Substantially reworded
14of those kept
Section length
25k wordsItem 1A

What the changes say

  • Linzess is subject to Medicare price negotiations setting a net price of $136 effective January 1, 2027.
  • Apraglutide development and VectivBio integration carry significant regulatory and operational execution risks.
  • Indebtedness stands at $585.0 million with $215.5 million in cash.

What changed since the prior 10-K

New

  • NewRisks Related to LINZESS, Apraglutide and Other Product Candidates

    which included LINZESS, covered by Medicare Part D, for the second cycle of price negotiations, and on November 25, 2025, released the MFP for a 30-day equivalent supply of LINZESS. The MFP for a 30-day equivalent supply of LINZESS, which will become the new Medicare net price as of January 1, 2027, is set to $136

    CMS released a maximum fair price of $136 for Linzess under Medicare Part D price negotiations, taking effect January 1, 2027.

  • NewRisks Related to LINZESS, Apraglutide and Other Product Candidates

    We cannot give any assurance that apraglutide will receive regulatory approval, which is necessary before it can be commercialized

    Apraglutide, a long-acting GLP-2 analog for short bowel syndrome, requires extensive clinical development and regulatory approval before commercialization.

  • NewRisks Related to LINZESS, Apraglutide and Other Product Candidates

    apraglutide within any approved indications or develop apraglutide for the treatment of additional indications, which would materially adversely impact our business and prospects

    Onerous and unpredictable regulatory approval processes in the U.S. and E.U. could delay or prevent the approval of apraglutide.

  • NewRisks Related to LINZESS, Apraglutide and Other Product Candidates

    would be impacted negatively. Furthermore, if these measures prevent us or any of our partners from selling linaclotide on a profitable basis in a particular country, they could prevent the commercial launch or continued sale of linaclotide in that country

    Partners AbbVie, Astellas, and AstraZeneca commercialize Constella and Linzess internationally, and pricing failures could hurt revenue.

  • NewRisks Related to the VectivBio Acquisition

    We may not realize the expected benefits and anticipated synergies of the VectivBio Acquisition

    We may fail to realize the expected benefits, synergies, or commercial success from the VectivBio Acquisition.

  • NewRisks Related to Our Dependence on Third Parties

    the availability of raw materials or a change in raw material suppliers could result in production disruptions, delays or higher costs with consequent adverse effects on us

    Manufacturing pharmaceutical products requires complex supply chains, and raw material or manufacturing disruptions could adversely affect us.

  • NewRisks Related to Our Dependence on Third Parties

    period of reduced efficiency or performance by our operations and commercialization teams, which could adversely affect our ability to commercialize LINZESS

    We lack international operational capabilities and rely heavily on third-party contract research organizations to conduct clinical trials.

  • NewRisks Related to Intellectual Property

    relationship with our licensor, the scope of our intellectual property or technology rights could be narrowed and we could lose license rights that are important to our business

    Licensing intellectual property involves complex legal issues, and disputes could narrow the scope of our technology rights.

  • NewRisks Related to Intellectual Property

    major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process

    Generic drug manufacturers have filed ANDAs with Paragraph IV certifications against Linzess, leading to expensive patent litigation.

  • NewRisks Related to Our Finances and Capital Requirements

    characterized by a high cost of living. As such, we could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment efforts, which may or may not be successful

    We may have difficulty attracting experienced personnel due to high cost of living and competing advisory commitments.

  • NewRisks Related to Our Finances and Capital Requirements

    deter a potential acquirer from conducting a solicitation of proxies to elect such acquirer’s own slate of directors or otherwise attempting to obtain control of our company

    Charter provisions and Delaware law include anti-takeover defenses like prohibitions on written consent and high voting thresholds.

  • NewRisks Related to Our Finances and Capital Requirements

    If we identify a material weakness in our internal control over financial reporting, it could have an adverse effect on our business and financial results, and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our Class A Common Stock

    Identifying a material weakness in internal control over financial reporting could adversely affect our financial results and stock price.

Dropped

  • DroppedRisks Related to LINZESS, Apraglutide and Other Product Candidates

    Adoption of new healthcare reform legislation at the federal or state level could negatively affect demand for, or pricing of, our products or product candidates if approved for sale

  • DroppedRisks Related to LINZESS, Apraglutide and Other Product Candidates

    Upon the closing of the VectivBio Acquisition, we added apraglutide, a next generation, long-acting GLP-2 analog in development for SBS patients who are dependent on PS, to our pipeline

  • DroppedRisks Related to LINZESS, Apraglutide and Other Product Candidates

    U.S. FDA or in other countries or harm linaclotide’s reputation in the marketplace, each of which could materially harm our revenues from linaclotide

  • DroppedRisks Related to Our Growth Strategy

    If we are unable to execute on our strategy to in-license or acquire externally developed products or product candidates, or engage in other transactions with value creation potential, our business and prospects would be materially adversely affected

    Adoption of new healthcare reform legislation at federal or state levels.

  • DroppedRisks Related to the VectivBio Acquisition

    In December 2023, we completed the VectivBio Acquisition. We may not realize the expected benefits from such acquisition because of integration difficulties or other challenges

  • DroppedRisks Related to Regulatory, Legal and Compliance Matters

    individual states have begun establishing Prescription Drug Affordability Boards (or similar entities) to review high-cost drugs and, in some cases, set upper payment limits. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation

    Adding apraglutide to the pipeline upon closing the VectivBio Acquisition.

  • DroppedRisks Related to Intellectual Property

    future. For example, such changes may increase the costs and complexity associated with obtaining, enforcing or defending our patents, including in ANDA litigation

  • DroppedRisks Related to Intellectual Property

    our partners, misappropriation of our proprietary rights, particularly in countries where the laws may not protect those rights as fully as in the U.S

    Pipeline strength depending on outcomes of studies and regulatory approvals like apraglutide.

  • DroppedRisks Related to Our Finances and Capital Requirements

    borrowed $400.0 million to fund a portion of the consideration paid to purchase VectivBio’s outstanding ordinary shares in connection with the VectivBio Acquisition

Reworded

  • 95% rewrittenRisks Related to Our Finances and Capital Requirements

    As of December 31, 2025, we had total indebtedness of $585.0 million and available cash and cash equivalents of $215.5 million

    Updated total indebtedness figure to $585.0 million and available cash to $215.5 million as of December 31, 2025, with $385.0 million principal remaining on the credit facility.

    Was: As of December 31, 2024, we had total indebtedness of $585.0 million and available cash and cash equivalents of $88.6 million

  • 87% rewrittenRisks Related to Our Finances and Capital Requirements

    Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could negatively impact the market price of our Class A Common Stock

    Retained anti-takeover provisions description under charter documents and Delaware law without substantive changes to the core text.

  • 86% rewrittenRisks Related to Our Dependence on Third Parties

    Manufacturers of our products may be unable to comply with these GMP requirements and with other regulatory requirements. We have little control over compliance with these regulations and standards by our partners and the third-party manufacturers we or our partners engage

    Retained third-party and partner GMP compliance risks for drug-device combination products without substantive text changes.

  • 81% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    We intend to explore further linaclotide development opportunities as well as to advance the development of our other pipeline programs, such as apraglutide, through internal or external opportunities

    Added FDA approval of Linzess in November 2025 for IBS-C in patients aged 7 and older.

    Was: As part of our growth strategy, we intend to explore further linaclotide development opportunities as well as to advance the development of our other pipeline programs, such as apraglutide, through internal or external opportunities

  • 73% rewrittenRisks Related to Regulatory, Legal and Compliance Matters

    If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected

    Retained healthcare and anti-kickback compliance risk disclosures without substantive text changes.

  • 64% rewrittenRisks Related to Intellectual Property

    We may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may harm our business

    Retained orphan drug designation and market exclusivity risk disclosures without substantive text changes.

  • 60% rewrittenRisks Related to Intellectual Property

    Our commercial success depends on our ability, and the ability of our partners, to develop, manufacture, market and sell our products and use our proprietary technologies without infringing the proprietary rights of third parties

    Retained third-party patent infringement risk disclosures for Linzess and apraglutide without substantive text changes.

  • 59% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, our products’ or product candidates’ commercial success

    Retained healthcare reform and PPACA impact disclosures without substantive text changes.

  • 55% rewrittenRisks Related to Our Finances and Capital Requirements

    We may not be able to manage our business effectively if we lose any of our current management team or if we are unable to attract, motivate and retain key personnel

  • 37% rewrittenRisks Related to Intellectual Property

    Our success depends on our ability to obtain and maintain sufficient patent protection for our products and product candidates, preserve our trade secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others

  • 36% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    We must work effectively and collaboratively with AbbVie to market and sell LINZESS in the U.S., and we must adapt our commercial model and market strategy to the evolving landscape for LINZESS to achieve its maximum commercial potential

  • 36% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their development, create unpredictable clinical trial results, impact their regulatory approval or limit their commercial potential

    Was: Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their development, create unpredictable clinical trial results, impact its regulatory approval or limit their commercial potential

  • 35% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    We are highly dependent on the commercial success of LINZESS (linaclotide) in the U.S. for the foreseeable future

  • 25% rewrittenRisks Related to LINZESS, Apraglutide and Other Product Candidates

    We are subject to uncertainty relating to pricing and reimbursement policies in the U.S., including recent and future healthcare reform measures, which, if not favorable for our products, could hinder or prevent our products’ commercial success

All 46 risk factors

Headings as the filing states them, in filing order.

Risks Related to LINZESS, Apraglutide and Other Product Candidates

  1. 01We are highly dependent on the commercial success of LINZESS (linaclotide) in the U.S. for the foreseeable future35% rewritten
  2. 02We are subject to uncertainty relating to pricing and reimbursement policies in the U.S., including recent and future healthcare reform measures, which, if not favorable for our products, could hinder or prevent our products’ commercial success25% rewritten
  3. 03Healthcare reform and other governmental and private payor initiatives may have an adverse effect upon, and could prevent, our products’ or product candidates’ commercial success59% rewritten
  4. 04which included LINZESS, covered by Medicare Part D, for the second cycle of price negotiations, and on November 25, 2025, released the MFP for a 30-day equivalent supply of LINZESS. The MFP for a 30-day equivalent supply of LINZESS, which will become the new Medicare net price as of January 1, 2027, is set to $136New
  5. 05We must work effectively and collaboratively with AbbVie to market and sell LINZESS in the U.S., and we must adapt our commercial model and market strategy to the evolving landscape for LINZESS to achieve its maximum commercial potential36% rewritten
  6. 06We cannot give any assurance that apraglutide will receive regulatory approval, which is necessary before it can be commercializedNew
  7. 07apraglutide within any approved indications or develop apraglutide for the treatment of additional indications, which would materially adversely impact our business and prospectsNew
  8. 08We intend to explore further linaclotide development opportunities as well as to advance the development of our other pipeline programs, such as apraglutide, through internal or external opportunities81% rewritten
  9. 09Delays in the completion of clinical testing of any of our products or product candidates could result in increased costs and could delay or limit our ability to generate revenues
  10. 10The pricing of apraglutide and our other product candidates, if and when approved for marketing, will depend in part on pricing and reimbursement strategies adopted by our competitors
  11. 11We face competition and new products may emerge that provide different or better alternatives for treatment of the conditions that our products are approved to treat
  12. 12Our products or product candidates may cause undesirable side effects or have other properties that could delay or prevent their development, create unpredictable clinical trial results, impact their regulatory approval or limit their commercial potential36% rewritten
  13. 13would be impacted negatively. Furthermore, if these measures prevent us or any of our partners from selling linaclotide on a profitable basis in a particular country, they could prevent the commercial launch or continued sale of linaclotide in that countryNew
  14. 14Even though linaclotide is approved for marketing in the U.S. and in a number of other countries, we or our partners may never receive approval to commercialize linaclotide in additional parts of the world
  15. 15If we are unable to successfully partner with other companies to develop and commercialize products and/or product candidates, our ability to grow would be impaired and our business would be adversely affected

Risks Related to the VectivBio Acquisition

  1. 16We may not realize the expected benefits and anticipated synergies of the VectivBio AcquisitionNew

Risks Related to Our Dependence on Third Parties

  1. 17Manufacturers of our products may be unable to comply with these GMP requirements and with other regulatory requirements. We have little control over compliance with these regulations and standards by our partners and the third-party manufacturers we or our partners engage86% rewritten
  2. 18the availability of raw materials or a change in raw material suppliers could result in production disruptions, delays or higher costs with consequent adverse effects on usNew
  3. 19period of reduced efficiency or performance by our operations and commercialization teams, which could adversely affect our ability to commercialize LINZESSNew

Risks Related to Regulatory, Legal and Compliance Matters

  1. 20We face potential product liability exposure, and, if claims brought against us are successful, we could incur substantial liabilities
  2. 21We will incur significant liability if it is determined that we are promoting any “off-label” uses of our products
  3. 22If we fail to comply with healthcare and other regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected73% rewritten
  4. 23The VectivBio Acquisition increases our exposure to doing business in foreign jurisdictions

Risks Related to Intellectual Property

  1. 24Limitations on our ability to obtain patent protection and/or the patent rights relating to our products and our product candidates may limit our ability to prevent third parties from competing against us
  2. 25Our success depends on our ability to obtain and maintain sufficient patent protection for our products and product candidates, preserve our trade secrets, prevent third parties from infringing upon our proprietary rights and operate without infringing upon the proprietary rights of others37% rewritten
  3. 26Our commercial success depends on our ability, and the ability of our partners, to develop, manufacture, market and sell our products and use our proprietary technologies without infringing the proprietary rights of third parties60% rewritten
  4. 27relationship with our licensor, the scope of our intellectual property or technology rights could be narrowed and we could lose license rights that are important to our businessNew
  5. 28We may be unable to maintain the benefits associated with orphan drug designation, including market exclusivity, which may harm our business64% rewritten
  6. 29major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval processNew

Risks Related to Our Finances and Capital Requirements

  1. 30We incurred significant losses from our inception in 1998 through the year ended December 31, 2018, and we may incur losses in future periods
  2. 31We may need additional funding and may be unable to raise capital when needed, which could cause us to delay, reduce or eliminate our corporate or product development or commercialization efforts
  3. 32Our ability to pay principal of and interest on our outstanding debt will depend in part on the receipt of payments from AbbVie under our collaboration agreement for North America
  4. 33As of December 31, 2025, we had total indebtedness of $585.0 million and available cash and cash equivalents of $215.5 million95% rewritten
  5. 34To the extent we become subject to such covenants, our ability to comply with such covenants in future periods will depend on our ongoing financial and operating performance, which in turn will be subject to economic conditions and to financial, market and competitive factors, many of which are beyond our control
  6. 35The capped call transactions entered into in connection with our Convertible Senior Notes may affect the value of our Class A Common Stock
  7. 36Our quarterly and annual operating results may fluctuate significantly
  8. 37Our ability to use foreign tax loss carryforwards acquired in the VectivBio Acquisition may be limited
  9. 38If the distribution of the shares of Cyclerion Therapeutics, Inc., or Cyclerion, common stock in connection with the Separation is not generally tax- free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities
  10. 39We may not be able to manage our business effectively if we lose any of our current management team or if we are unable to attract, motivate and retain key personnel55% rewritten
  11. 40characterized by a high cost of living. As such, we could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment efforts, which may or may not be successfulNew
  12. 41Security breaches and other disruptions to our information technology structure could compromise our information, disrupt our business and expose us to liability, which would cause our business and reputation to suffer
  13. 42Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could negatively impact the market price of our Class A Common Stock87% rewritten
  14. 43deter a potential acquirer from conducting a solicitation of proxies to elect such acquirer’s own slate of directors or otherwise attempting to obtain control of our companyNew
  15. 44If we identify a material weakness in our internal control over financial reporting, it could have an adverse effect on our business and financial results, and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our Class A Common StockNew
  16. 45We expect that the price of our Class A Common Stock will fluctuate substantially
  17. 46Our business could be negatively affected as a result of a proxy contest or certain other stockholder actions

Other Ironwood Pharmaceuticals 10-Ks

  • FY2024 10-K risk factors
    43 risks

    Heavy commercial reliance on LINZESS partnered with AbbVie. Integration risks and debt from the VectivBio acquisition of apraglutide. Stringent pricing, reimbursement, and healthcare reform pressures.

    Filed Mar 31, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.